KR20220170519A - Composition for ameliorating fatigue comprising Cinnamomum verum extract as effective component - Google Patents

Abstract

The present invention relates to a composition for ameliorating fatigue, comprising a Cinnamomum verum extract as an effective component. The Cinnamomum verum extract which is an effective component, of the present invention, has little cytotoxicity, reduces the expression level of inflammatory factors TNFα and IL-2, which can cause fatigue or depression, and reduces the content of corticosterone increased by LPS treatment. Meanwhile, after administering the Cinnamomum verum extract of the present invention to an animal model, it was confirmed that the immobility time in forced swimming and the immobility time in tail hanging were significantly reduced. Therefore, the composition of the present invention can be useful as a health functional food composition for ameliorating fatigue, and can be particularly useful for fatigue caused by depression.

Description

Composition for ameliorating fatigue comprising Cinnamomum verum extract as effective component}

The present invention relates to a composition for improving fatigue comprising a broiler extract as an active ingredient.

Fatigue is generally defined as abnormal exhaustion after daily activities, a state of inability to perform tasks that require sustained effort or concentration due to lack of energy, or a general lack of energy to the extent that daily activities cannot be performed. If it lasts more than 1 month, it is called prolonged fatigue, and if it lasts more than 6 months, it is called chronic fatigue.

Unlike transient fatigue, which is recovered with a short rest, chronic fatigue syndrome does not improve even after rest, and fatigue that makes the patient very debilitating continues. The cause of Chronic Fatigue Syndrome is still unknown. However, as related diseases, various infections including viral infections, transient trauma or shock, extreme stress, and toxic substances are being discussed. Recently, it has been argued that the disease is caused by a disorder of the central nervous system. The basis for this is that symptoms such as concentration disorder, attention disorder, memory disorder, and sensory abnormality are frequent in patients with chronic fatigue syndrome, among which 5 to 15 It can be pointed out that symptoms such as temporary paralysis, visual impairment, motor incoordination, or confusion appear within the first 6 months of onset in 10% of patients. Since these symptoms appear when there is something wrong with the central nervous system, it suggests a connection between chronic fatigue syndrome and the central nervous system. In addition, a theory has been raised that cases in which cerebral blood flow is reduced in patients with chronic fatigue syndrome are found in the SPECT test or abnormal findings of various neurotransmitters are found, but the cause has not yet been clarified.

On the other hand, broiler ( Cinnamomum verum ) is the stem bark of Lauraceae, as it is or slightly removed. Studies on the components or physiological activities of broiler chicken are known to have antidiabetic, anti-infectious, anti-fibrotic, melanin synthesis inhibition, bone formation promotion and antibiotic effects, and protein kinase C (PKC), Inhibits the expression of vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2), mitogen-activated protein kinase (MAPK (ERK1/2)) and inhibit phosphorylation of AKT.

As a technique related to broiler extract, Korean Patent Publication No. 2006-0030535 discloses a composition containing a broiler extract having anti-anxiety activity, and Korean Patent No. 1987821 discloses a mixed extract of broiler and silkworm as an active ingredient. Although a composition for enhancing immunity has been disclosed, a composition for improving fatigue comprising the broiler extract of the present invention as an active ingredient has not yet been disclosed.

The present invention was derived from the above needs, and the present invention provides a composition for improving fatigue comprising a broiler extract as an active ingredient, and the broiler extract has little cytotoxicity and is an inflammatory factor that can cause fatigue or depression. It can reduce the expression level of TNFα and IL-2, reduce the content of Corticosterone increased by LPS treatment, and after administering the broiler extract of the present invention to an animal model, in forced swimming The present invention was completed by confirming that the immobility time of and the immobility time in tail hanging were significantly reduced.

In order to achieve the above object, the present invention provides a health functional food composition for improving fatigue containing broiler extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating chronic fatigue syndrome comprising a broiler extract as an active ingredient.

The present invention relates to a composition for improving fatigue comprising a broiler extract as an active ingredient. In addition, after administering the broiler extract of the present invention to an animal model, immobility time in forced swimming and tail hanging tests can be reduced. has the effect of significantly reducing

1 is a result of confirming the cell viability of the broiler extract of the present invention.
Figure 2 is the result of confirming the immobility time (A) in forced swimming and the immobility time (B) in tail hanging according to the administration of the broiler extract (CV) of the present invention. ### indicates a statistically significant increase in immobility time in forced swimming or tail hanging in the LPS-treated group (+) compared to the untreated normal group (-), p<0.001. *, **, *** means that the immobility time in forced swimming or tail hanging of the broiler extract-administered group (CV) or the positive control group (Fluoxetine) of the present invention was statistically significantly reduced compared to the LPS group. p<0.05, ** p<0.01, *** p<0.001.
Figure 3 is the result of confirming the change in the expression level of the inflammatory factors TNFα (A) and IL-2 (B) according to the administration of the broiler extract (CV) of the present invention. #, ### indicates a statistically significant increase in the expression levels of TNFα and IL-2 in the LPS-treated group (+) compared to the untreated normal group (-), # is p<0.05, ### is p<0.001. *, **, *** indicates a statistically significant decrease in the expression levels of TNFα and IL-2 in the broiler extract-administered group (CV) or the positive control group (Fluoxetine) of the present invention compared to the LPS group, * indicates p<0.05 , ** is p <0.01, *** is p <0.001.
Figure 4 is the result of confirming the change in blood content of corticosterone according to the administration of the broiler extract (CV) of the present invention. # indicates a statistically significant increase in the corticosterone content of the LPS-treated group (+) compared to the normal group (-) not treated, p<0.05. *, ** indicates that the corticosterone content of the broiler extract-administered group (CV) or the positive control group (Fluoxetine) of the present invention decreased statistically significantly compared to the LPS group, * is p<0.05, and ** is p< is 0.01.

The present invention relates to a health functional food composition for improving fatigue containing a broiler extract as an active ingredient.

The broiler extract may be prepared by a method comprising the following steps, but is not limited thereto:

(1) extracting by adding an extraction solvent to the dried broiler;

(2) filtering the extract of step (1); and

(3) preparing an extract by concentrating and drying the filtered extract of step (2).

In the step (1), the extraction solvent is preferably selected from water, C ₁ ~ C ₄ lower alcohol or a mixture thereof, more preferably ethanol, and even more preferably 70% ( v / v ) ethanol. Not limited to this. In the preparation method, all conventional methods known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction may be used as the extraction method. The extraction solvent is preferably extracted by adding 1 to 20 times the weight of the broiler, more preferably 5 to 15 times, and even more preferably 10 times. The extraction temperature is preferably 20 to 100 ° C, but is not limited thereto. In addition, the extraction time is preferably 1 to 48 hours, more preferably 1 to 24 hours, and most preferably 3 hours, but is not limited thereto. In the above method, the concentration in step (3) is preferably performed using a vacuum rotary evaporator or a vacuum rotary evaporator, but is not limited thereto. In addition, drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, more preferably freeze drying, but not limited thereto.

The fatigue is characterized by fatigue caused by inflammatory depression, and the broiler extract is characterized by reducing the secretion of corticosterone, but is not limited thereto.

The health functional food composition according to the present invention may be added to food as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (for prevention or improvement). In general, the amount of the active ingredient contained in the health functional food may be added to 0.1 to 90 parts by weight of the total weight of the health functional food. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. .

The health functional food composition of the present invention may be prepared in any one formulation selected from beverages, pills, tablets, capsules, and powders, and when used as a beverage, the above as an essential component in the indicated ratio. Other than containing the active ingredient, there are no particular restrictions on other ingredients, and various flavoring agents or natural carbohydrates may be included as additional ingredients, as in conventional beverages. Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (eg rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. there is.

The health functional food composition of the present invention, in addition to the above active ingredients, contains nutrients, vitamins, electrolytes, flavors, colorants, enhancers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, and stabilizers. It may further contain at least one selected from topical agents, preservatives, glycerin, alcohol, and carbonation agents used in carbonated beverages. In addition, the health functional food composition of the present invention may contain fruit flesh for preparing natural fruit juice and vegetable beverages. The pulp may be used independently or in combination. The ratio of the various additives is not critical, but is generally selected in the range of 0.1 to 20 parts by weight per 100 parts by weight of the broiler extract of the present invention.

In addition, the present invention relates to a pharmaceutical composition for preventing or treating chronic fatigue syndrome comprising a broiler extract as an active ingredient.

The pharmaceutical composition of the present invention may be in various oral or parenteral dosage forms. When formulating the composition, it may be prepared using commonly used carriers, excipients or diluents, but is not limited thereto. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, or syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, or preservatives may be included. can Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, freeze-dried formulations, suppositories, and the like. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As the base of the suppository, witepsol, macrogol, tween 61, cacao paper, laurin paper, glycerol, gelatin, etc. may be used.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it is preferable to select an external skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine epidural or intracerebrovascular injection method, but is limited thereto. I never do that. The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, a pharmacologically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the type, severity, activity of the drug, and drug sensitivity, time of administration, route of administration and excretion rate, duration of treatment, factors including concomitantly used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art.

The dose of the composition of the present invention varies in its range depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of the disease, and the daily dose is based on the amount of broiler extract 0.01 to 1000 mg/kg, preferably 30 to 500 mg/kg, and more preferably 50 to 300 mg/kg, and may be administered 1 to 6 times a day, but the route of administration, the severity of chronic fatigue, Since it may increase or decrease according to gender, weight, age, etc., the dosage is not limited to the scope of the present invention in any way.

Hereinafter, the present invention will be described in more detail using examples. These examples are only for explaining the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.

Example 1. Preparation of Broiler Ethanol Extract

After hot air drying of 500 g of broiler chicken at 50 ° C. for 7 days, 10 times 70% ( v / v ) ethanol was added, followed by reflux cooling extraction and filtration twice for 3 hours each. Thereafter, the broiler extract was concentrated under reduced pressure at 45 ° C to remove ethanol, and then lyophilized at -80 ° C for 7 days to obtain a broiler extract.

Example 2. Analysis of cell viability according to treatment of broiler extract

For cell viability analysis, 1×10 ⁴ cells/ml of Human Jurkat cells were plated on a 96-well plate, cultured for 24 to 72 hours, and 0.1, 1, 5, and 10 mg/ml of broiler extract were added to each well. treated and incubated for 48 hours. Thereafter, the cell viability was analyzed by measuring the absorbance at 490 nm, and the experiment was repeated three times and expressed as the mean ± standard deviation.

As a result, as shown in FIG. 1, the broiler extract of the present invention showed little cytotoxicity.

Example 3. Analysis of behavioral changes in animal models according to the treatment of broiler extract

Mice (C57BL/6, n=8) were orally administered with 10 mg/kg of fluoxetine as a broiler extract or a positive control group for 10 days, and then intraperitoneally administered with LPS (1 mg/kg) to induce inflammation. On the third day, forced swimming and tail hanging were performed to confirm the immobility time.

(1) Assessment of forced swimming exercise

The weight-loaded forced swimming test of Moriura T et al. was supplemented and conducted as follows. As a device to evaluate forced swimming ability, a transparent plastic container with a diameter of 17 cm and a height of 27 cm was used. After filling with water, the temperature of the water was maintained at 27 ° C. I did it until it didn't touch the floor. In the swimming experiment, a weight corresponding to 5% of the body weight was fixed to the tail, and both the control group and the experimental group performed swimming at the same time after 1 hour of oral administration. The end of swimming was applied as the end point when the nose went below the water surface for 5 seconds.

(2) Assessment of tail hanging movement

A tail hanging device was installed in an open box of 20 cm x 25 cm x 30 cm size made of white acrylic, and mice in the experimental group and control group were suspended at a height where their tails would not touch the floor, and observed in the same environment for 6 minutes. The time to maintain immobility was measured. Measurements were made during the final 4 minutes, and after recording with a video camera, the overall movement was analyzed using video tracking software (SMART 3.0, Panlab, Spain).

As a result, as shown in FIG. 2, the immobility time of the broiler extract administration group of the present invention and the positive control group (Fluoxetine, 10 mg/kg/day) was statistically significantly reduced compared to the inflammation induction group in forced swimming and tail hanging.

Example 4. Confirmation of changes in TNFα and IL-2 secretion according to the treatment of broiler extract

After oral administration of broiler extract to mice (C57BL/6, n=8) for 10 days, intraperitoneal administration of LPS (1 mg/kg) to induce inflammation, the secretion of TNFα and IL-2 in serum was confirmed. did

As a result, as shown in FIG. 3, the amount of secretion of TNFα and IL-2 in the serum was also significantly reduced in the broiler extract-administered group.

Example 5. Confirmation of changes in the content of corticosterone

After oral administration of broiler extract to mice (C57BL/6, n=8) for 10 days, inflammation was induced by intraperitoneal administration of LPS (1mg/kg), and the secretion of corticosterone in serum was confirmed.

As a result, as shown in FIG. 4, the blood corticosterone content, which is a fatigue factor, was significantly reduced in the broiler extract administration group.

Claims (6)

Health functional food composition for fatigue improvement containing broiler extract as an active ingredient. The health functional food composition for improving fatigue according to claim 1, wherein the extraction solvent of the broiler extract is water, C ₁ ~ C ₄ lower alcohol, or a mixture thereof. The functional food composition for improving fatigue according to claim 1, wherein the fatigue is fatigue caused by inflammatory depression. The functional food composition for improving fatigue according to claim 1, wherein the broiler extract reduces the secretion of corticosterone. A pharmaceutical composition for preventing or treating chronic fatigue syndrome comprising a broiler extract as an active ingredient. The pharmaceutical composition for preventing or treating chronic fatigue syndrome according to claim 5, further comprising a carrier, excipient or diluent in addition to the broiler extract.

Images